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S U M M A R Y
Objective: This study assessed the impact of ertapenem and other carbapenems on mortality in patients
with monomicrobial extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) bacter-
emia.
Methods: This non-concurrent prospective study included adult patients with ESBL-EC bacteremia
during a 2.5-year period at a 2200-bed teaching hospital. We used a multivariate logistic regression
model and Cox’s proportional hazards model including propensity score analysis to assess variables
associated with 30-day mortality.
Results: Of 71 patients who met the study criteria, nine died within 3 days. Among the 62 remaining
patients who received deﬁnitive antimicrobial therapy, 13 died within 30 days. Male gender, ICU stay,
solid tumor, and primary bacteremia were independent predictors of 30-day mortality, whereas
deﬁnitive antimicrobial therapy using either ertapenem or imipenem/meropenem was protective
(p < 0.001 and p = 0.002, respectively). Adjustment by propensity score found that ertapenem appeared
to exhibit more favorable outcomes, but the difference fell short of statistical signiﬁcance (hazard ratio
0.02, p = 0.06). Inappropriate initial therapy was not a signiﬁcant predictor of mortality.
Conclusions: ICU stay, but not initial choice of empirical antimicrobial therapy, was a major predictor of
mortality. Using a carbapenem as deﬁnitive therapy was a protective factor for 30-day mortality. The
choice of ertapenem is reasonable for less severely-ill patients who are at risk of ESBL-EC bacteremia and
unlikely to have infection due to Pseudomonas aeruginosa.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Enterobacteriaceae that produce extended-spectrum beta-lac-
tamases (ESBLs) and are resistant to oxyimino-b-lactams (cefo-
taxime, ceftriaxone, ceftazidime, cefepime, and aztreonam) have
become a global concern.1–5 The increasing frequency of cross-
resistance to ﬂuoroquinolones and other antimicrobial agents
compromise the choice of empirical therapy.6 As noted by Paterson
and Rogers,7 there is an urgent need to conduct randomized,
controlled trials evaluating the treatment of multidrug-resistant
bacterial infections, though these are difﬁcult to perform.
The older generation of carbapenems (imipenem and mer-
openem) are currently considered to be the treatment of choice for* Corresponding author. Tel.: +886 2 2312 3456x65908; fax: +886 2 2397 1412.
E-mail address: yeechunchen@gmail.com (Y.-C. Chen).
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doi:10.1016/j.ijid.2011.09.019serious infections caused by ESBL-producing bacteria.8 However,
the actual evidence for this clinical practice is limited to case
reports and small retrospective series.9–11 A new carbapenem,
ertapenem, is a Pseudomonas-sparing antimicrobial agent with
comparable or slightly lower activity in vitro and in animal
models of infection by ESBL-producing bacteria.8 However,
comparative clinical trials between different carbapenems are
lacking.
Hence, this non-concurrent prospective study was undertaken
to determine the impact of using ertapenem and other carbape-
nems on mortality in a cohort of patients with monomicrobial
ESBL-producing Escherichia coli (ESBL-EC) bacteremia, after con-
trolling for the severity of underlying diseases and infection. In
view of the possible differences in baseline characteristics between
patients using ertapenem and other carbapenems as deﬁnitive
therapy, we also employed propensity score methods to control for
potential confounding factors.12,13ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study design and patient populations
This non-concurrent prospective study was conducted at the
National Taiwan University Hospital, a 2200-bed teaching hospital
in Taiwan, from January 1, 2005 to June 30, 2007. All adult patients
(16 years or older) with a positive blood culture for an ESBL-EC
were identiﬁed by the prospective hospital-wide healthcare-
associated infection surveillance. Only those patients who received
antimicrobial therapy during their ﬁrst monomicrobial bacteremic
episode were included in the analysis. Medical records were
reviewed using a standardized case record form for the collection
of data on all important variables including Charlson co-morbidity
index,14 length of hospital stay, site of acquisition (community-
acquired, healthcare-associated, or hospital-acquired infection),
intensive care unit (ICU) stay at the onset of infection, severity of
illness (Pittsburgh bacteremia score),15 primary site of infection,
initial antimicrobial therapy, use of carbapenems, and date of
death. The study was approved by the ethics board of the National
Taiwan University Hospital.
2.2. Bacteriology and antimicrobial susceptibility testing
E. coli was identiﬁed by standard microbiological methods.
Antimicrobial susceptibility was determined by the Kirby–Bauer
disk diffusion method. Isolates with decreased susceptibility to any
one of the three tested drugs (aztreonam, 27 mm; ceftazidime,
22 mm; ceftriaxone, 25 mm) based on inhibition zone dia-
meters were tested for ESBLs by double-disk method with disks
containing cefotaxime (30 mg), cefotaxime plus clavulanic acid
(30 mg plus 10 mg), ceftazidime (30 mg), and ceftazidime plus
clavulanic acid, in accordance with the Clinical and Laboratory
Standards Institute (CLSI) standards.16 Isolates were considered as
ESBL-positive when the addition of clavulanic acid resulted in a
5-mm increase in a zone diameter for either antimicrobial agent.
2.3. Deﬁnitions
Hospital-acquired infection was deﬁned as an infection that
occurred >48 h after admission to the hospital, or an infection that
occurred < 48 h after admission in patients who had been
transferred from another hospital. Infections with ESBL-EC
detected within the ﬁrst 48 h of hospitalization were classiﬁed
as ‘community-onset’ and were further classiﬁed into community-
acquired or healthcare-associated infection (modiﬁed from the
study of Siegman-Igra et al.17). Infections found in patients
admitted to the hospital from home without having been
hospitalized within the past 6 months and without a history of
undergoing an invasive procedure either just before or at the time
of admission, were categorized as truly community-acquired.
Healthcare-associated infections were deﬁned as infections in
patients discharged within the recent 6 months, infections
associated with invasive procedures performed just before or at
the time of admission, and infections in patients admitted from
nursing homes. The date of the ﬁrst blood culture yielding ESBL-EC
was considered as the onset of bacteremia. Early mortality was
deﬁned as death occurring within 3 days of the onset of infection.
The primary sites of infection were identiﬁed according to the US
Centers for Disease Control and Prevention (CDC) deﬁnitions.18 The
Charlson co-morbidity index was calculated for underlying
illnesses. Patients were deﬁned as immunosuppressed if the
absolute neutrophil count was <0.5  109 cells/l, the patient had a
hematological or other malignancy, or if the patient had received
corticosteroid therapy (equivalent to >20 mg prednisolone per
day) for at least 2 weeks, cancer chemotherapy, or radiationtherapy within 30 days before the onset of bacteremia. Any use of
antimicrobial agent for >48 h during the 3 months preceding the
index admission was considered as prior antimicrobial use. Septic
shock was deﬁned as the sepsis associated with organ dysfunction
and accompanied by persistent hypotension following volume
replacement.19 The severity of illness on the day when the blood
culture specimens were obtained was determined by the
Pittsburgh bacteremia score.15 Initial antimicrobial therapy refers
to the treatment that was administered empirically before in vitro
susceptibility test results were available. The initial treatment was
classiﬁed as inadequate if the infecting pathogen was non-
susceptible to the drug being administered, or if the treatment
was not given within 48 h after blood cultures were collected.
2.4. Statistical analysis
All statistical analyses were performed using SAS software
version 9.1.3 (SAS Institute Inc., Cary, NC, USA). A two-sided p-
value of 0.05 was considered statistically signiﬁcant. The
associations between categorical variables were analyzed with
the Chi-square test or Fisher’s exact test, whereas the means or
medians of continuous variables were compared between two
groups by the Mann–Whitney U-test. In addition to univariate
analyses, Cox’s proportional hazards model was conducted to
identify important predictors of 30-day mortality. Subset analysis
was performed to evaluate the impact of using ertapenem and
imipenem/meropenem on 30-day mortality. In view of the
possible differences in baseline characteristics between patients
using ertapenem and other carbapenems as deﬁnitive therapy, we
employed propensity score methods, where the predicted
probability of treatment with ertapenem was derived from
unconditional logistic regression utilizing a manual backward
elimination approach. Propensity scores provide a means of
balancing baseline covariates predictive of treatment, mitigating
the unequal chance of receiving ertapenem versus other carba-
penems, and are an efﬁcient method to control for confounding in
pharmacoepidemiologic analyses.
The goal of regression analysis was to ﬁnd parsimonious
regression models that ﬁt the observed data well. To ensure the
quality of analysis results, basic model-ﬁtting techniques for (1)
variable selection, (2) goodness-of-ﬁt (GOF) assessment, and (3)
regression diagnostics, were used in our regression analyses.
Speciﬁcally, the stepwise variable selection procedure was applied
to obtain the candidate ﬁnal regression model. All the potential
predictors of 30-day mortality were put on the variable list to be
selected, and the signiﬁcance levels for entry (SLE) and for stay
(SLS) were set to 0.15 or greater. Next, with the aid of substantive
knowledge, the signiﬁcance level was reduced to 0.05 to identify
manually the best candidate ﬁnal regression model. Any discrep-
ancy between the results of univariate analysis and multivariate
analysis was likely due to the confounding effects of the
uncontrolled covariates in the univariate analysis. Both the
adjusted generalized R2 and the Grønnesby–Borgan GOF test were
examined to assess the GOF of the ﬁtted Cox’s proportional hazards
model. Nonetheless, the value of adjusted generalized R2 for Cox’s
proportional hazards model is usually low. Larger p-values of
Grønnesby–Borgan GOF test indicate better ﬁts. Also, the statistical
tools for regression diagnostics including veriﬁcation of propor-
tional hazards assumption, residual analysis, detection of inﬂuen-
tial cases, and checking for multicollinearity were used to identify
model or data problems.
3. Results
ESBL-EC were isolated from the blood samples of 97 patients
during the 2.5-year study period (38.8 cases per year). Five of these
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Figure 1. Flow chart showing the identiﬁcation of the study population.
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hospitals soon after blood cultures were collected (Figure 1). One
patient had incomplete medical records, and data regarding the
types of antimicrobial agents used could not be retrieved. Of the
remaining 91 patients, 97.9% had their blood isolates susceptible in
vitro to ertapenem (Table 1). Twenty of these patients had
polymicrobial bacteremia. The remaining 71 patients had mono-
microbial ESBL-EC bacteremia and met the study criteria; these
patients were analyzed further. Of the 71 patients, nine (12.7%)
died within 3 days after onset of bacteremia, thus leaving 62
patients who were able to receive deﬁnitive antimicrobial therapy.
These included imipenem (n = 17), meropenem (n = 5), ertapenem
(n = 27), cephamycins (n = 2), non-cephamycin cephalosporins
(n = 5), ﬂuoroquinolones (n = 3), and b-lactam/b-lactamase inhi-
bitors (n = 3). Among them, 13 (18.3%) died during the 30-day
study period.
3.1. 30-day mortality
The potential risk factors for 30-day mortality are shown in
Table 2. By ﬁtting Cox’s proportional hazards model, male gender
(p = 0.02), ICU stay at bacteremia onset (p = 0.0001), solid tumor
(p = 0.003), and primary bacteremia (p = 0.006) were signiﬁcantTable 1
Susceptibility proﬁle of 91 ESBL-producing E. coli bacteremia isolates
Antibiotic Susceptible rate
Cefmetazole 77.7%
Amoxicillin/clavulanate 18.8%
Ertapenem 97.9%
Gentamicin 33.3%
Amikacin 92.7%
Ciproﬂoxacin 38.5%
Piperacillin/tazobactam 44.8%
ESBL, extended-spectrum beta-lactamase.predictors of 30-day mortality (Table 3). On the other hand,
deﬁnitive antimicrobial therapy using either ertapenem
(p < 0.0001) or imipenem/meropenem (p = 0.002) was shown to
be protective.
3.2. Impact of different carbapenems on mortality
Further subset analysis was performed to evaluate the impact of
using different carbapenems as deﬁnitive therapy on survival. The
clinical characteristics and outcomes in patients treated with
imipenem/meropenem and ertapenem are illustrated in Table 4.
The 30-day mortality for 27 patients who received ertapenem was
7.4% and that of 22 patients treated with imipenem or meropenem
was 31.8%. However, patients treated with imipenem or mer-
openem were more likely to be immunosuppressed (63.6% vs.
22.2%, p = 0.003) and to develop septic shock at bacteremia onset
(31.8% vs. 11.1%, p = 0.09) than those receiving ertapenem. These
underlying differences could have biased our assessment of the
true impact of different carbapenems on outcomes. As a result, a
propensity scoring system was used to minimize the inﬂuence of
pertinent confounders. By Cox’s proportional hazards model, male
gender, ICU stay at bacteremia onset, solid tumor, and primary
bacteremia were independent risk factors for 30-day mortality
among patients treated with carbapenems as deﬁnitive therapy
(Table 3). Patients who received ertapenem appeared to exhibit
more favorable outcomes, but the difference fell short of statistical
signiﬁcance (hazard ratio 0.02, p = 0.06).
4. Discussion
The present study demonstrated the predictors of 30-day
mortality associated with ESBL-EC bacteremia. Among these
parameters, deﬁnitive antimicrobial therapy using carbapenems
was the only modiﬁable factor to decrease the mortality rate. We
found that inappropriate initial antimicrobial therapy was not a
Table 2
Univariate analysis of the risk factors associated with 30-day mortality in patients with ESBL-producing E. coli monomicrobial bacteremia
Variable Nonsurvivors (n = 13)
n (%) or median (range)
Survivors (n = 49)
n (%) or median (range)
HR (95% CI) p-Value
Demographics
Age 65 years 7 (53.8) 27 (55.1) 0.96 (0.328–2.854) 0.94
Male gender 8 (61.5) 23 (46.9) 1.71 (0.56–5.24) 0.35
Length of hospital stay before onset (days) 6 (1–168) 1 (1–161) 1.01 (0.99–1.02) 0.44
Epidemiological category
Community-acquired 0 (0) 6 (12.2) 0.04 (0–832.99) 0.53
Healthcare-associated 13 (100) 43 (87.8) 1.54 (0.42–5.60) 0.52
Hospital-acquired 10 (76.9) 26 (53.1) 2.06 (0.56–7.57) 0.27
ICU stay at onset 4 (30.8) 3 (6.1) 3.75 (1.15–12.20) 0.03
Co-morbidity
Diabetes mellitus 1 (7.7) 13 (26.5) 0.29 (0.04–2.25) 0.24
Renal failure 2 (15.4) 10 (20.4) 0.58 (0.13–2.62) 0.48
Liver cirrhosis 2 (15.4) 8 (16.3) 0.75 (0.17–3.41) 0.71
Solid tumors 7 (53.8) 20 (40.8) 1.53 (0.51–4.559) 0.45
Hematological malignancy 3 (23.1) 9 (18.4) 1.00 (0.27–3.72) 1.00
Immunosuppression 11 (84.6) 17 (34.7) 6.84 (1.51–31.01) 0.01
Charlson co-morbidity index 4 (2–8) 3 (0–10) 1.02 (0.81–1.28) 0.85
Primary site of infection
Urinary tract 3 (23.1) 23 (46.9) 0.61 (0.17–2.26) 0.46
Intra-abdominal 2 (15.4) 14 (28.6) 0.33 (0.07–1.51) 0.15
Primary bacteremia 6 (46.2) 8 (16.3) 3.32 (1.11–9.91) 0.03
Other 2 (15.4) 4 (8.2) 1.35 (0.30–6.16) 0.70
Antimicrobial therapy
Inappropriate initial therapy 9 (69.2) 29 (59.2) 1.61 (0.50–5.24) 0.43
Deﬁnitive therapy using carbapenems 9 (69.2) 40 (81.6) 0.20 (0.06–0.68) 0.01
Imipenem/meropenem 7 (77.8) 15 (37.5) 4.97 (1.03–24.03) 0.04
Ertapenem 2 (22.2) 25 (62.5) 0.16 (0.04–0.73) 0.02
Severity of illness
Pittsburgh bacteremia score 4 5 (38.5) 9 (18.4) 1.77 (0.58–5.46) 0.32
Pittsburgh bacteremia score 2 (0–6) 1 (0–6) 1.24 (0.95–1.62) 0.11
Septic shock 5 (38.5) 6 (12.2) 3.66 (1.05–12.68) 0.04
ESBL, extended-spectrum beta-lactamase; HR, hazards ratio; CI, conﬁdence interval; ICU, intensive care unit.
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outcomes were determined primarily by patient co-morbid
conditions including ICU stay and malignancy.
The impact of inappropriate initial antimicrobial therapy on
infections caused by ESBL-producing Enterobacteriaceae is contro-
versial. Tumbarello et al. found that signiﬁcant predictors of
mortality included inadequate initial therapy in bacteremia caused
by ESBL-producing Enterobacteriaceae.20,21 Pena et al. and Hyle
et al. also demonstrated that inadequate empirical antibiotic
therapy was an independent risk factor for mortality when limitedTable 3
Multivariate analyses of the predictors of 30-day mortality using Cox’s proportional
hazards models in patients with ESBL-producing E. coli monomicrobial bacteremia
Variablea HR 95% CI p-Value
Predictors of 30-day mortalityb (n = 62)
Male gender 6.06 1.28–28.67 0.02
ICU stay at bacteremia onset 73.09 8.03–665.25 0.0001
Solid tumor 54.76 4.09–732.44 0.003
Primary bacteremia 40.14 2.94–548.58 0.006
Imipenem/meropenem use 0.03 0.003–0.25 0.002
Ertapenem use 0.001 0.001–0.03 <0.0001
Predictors of 30-day mortality among patients having received carbapenemsc
(n = 49)
Male gender 30.12 2.17–418.34 0.01
ICU stay at bacteremia onset 2210.70 11.30–432355.8 0.004
Solid tumor 37.38 2.27–614.97 0.01
Primary bacteremia 23.68 1.91–293.93 0.01
Ertapenem 0.02 0.001–1.10 0.06
ESBL, extended-spectrum beta-lactamase; HR, hazards ratio; CI, conﬁdence
interval; ICU, intensive care unit.
a Only variables with statistical signiﬁcance in multivariate analysis are shown.
b Adjusted R2 = 0.65.
c Adjusted R2 = 0.74.to patients without urinary tract infections.22,23 However, other
investigators did not conﬁrm these ﬁndings.24–26 In a recent study
focusing on nosocomial bacteremia caused by ESBL-EC, mortality
was associated with disease severity, the primary source of
bacteremia, and infections with highly resistant isolates rather
than inappropriate therapy.27 These differences might be
explained by the inclusion of non-blood isolates, indicating the
possibility of colonization instead of true infection, and infections
caused by a variety of Enterobacteriaceae.
The current ‘gold standard’ treatment for ESBL-producing
Gram-negative bacteremia is carbapenem.8,28 However, only
limited observational data exist regarding the clinical outcome
with carbapenem.9–11 Studies addressing the clinical efﬁcacy of
ertapenem are exceedingly scarce.26 Nevertheless, recent reports
suggest favorable clinical responses after having used ertapenem
against ESBL-producing organisms.29,30 The present study dem-
onstrated that treatment with carbapenem was protective.
Furthermore, patients who received ertapenem as deﬁnitive
therapy had a lower mortality rate compared with individuals
treated with other carbapenems. Notably, a larger proportion of
patients were immunocompromised and more severely ill in the
imipenem/meropenem group. After having adjusted for potential
confounders using a propensity score, ertapenem remained at
least non-inferior to imipenem/ertapenem in terms of 30-day
mortality.
Previous studies have illustrated that prior use of imipenem or
meropenem is associated with colonization or infection due to
multidrug-resistant Acinetobacter baumannii, Pseudomonas aerugi-
nosa, and Stenotrophomonas maltophilia.31–36 Given that ertape-
nem has limited activity against non-fermentative Gram-negative
bacilli, the compound has the potential to reduce the occurrence of
bacterial resistance by decreasing the usage and selective pressure
Table 4
Comparisons of the baseline characteristics and mortality among 49 patients with
ESBL-producing E. coli monomicrobial bacteremia according to the use of deﬁnitive
antimicrobial therapy
Patient characteristics Ertapenem
(n = 27)
Imipenem/
meropenem
(n = 22)
p-Value
Demographic information
Age 65 years 14 (51.9) 13 (59.1) 0.85
Male gender 15 (55.6) 10 (45.5) 0.31
Epidemiological category of the infection
Community-acquired 3 (11.1) 2 (9.1) 1.00
Healthcare-associated 10 (37.0) 7 (31.8) 0.70
Hospital-acquired 14 (51.9) 13 (59.1) 0.61
ICU stay at onset 4 (14.8) 4 (18.2) 1.00
Co-morbidity
Charlson co-morbidity index,
median (range)
4 (0–9) 3 (1–10) 0.1
Immunosuppression 6 (22.2) 14 (63.6) 0.003
Primary site of infection
Urinary tract 11 (40.7) 8 (36.4) 0.75
Intra-abdominal 8 (29.6) 6 (27.3) 0.86
Primary bacteremia 5 (18.5) 7 (31.8) 0.33
Other 3 (11.1) 2 (9.1) 0.62
Severity of bacteremia at onset
Pittsburgh bacteremia score  4 5 (18.5) 8 (36.4) 0.20
Septic shock 3 (11.1) 7 (31.8) 0.09
Initial antimicrobial therapy
Inadequate 14 (51.9) 9 (40.9) 0.45
30-day mortality 2 (7.4) 7 (31.8) 0.06
ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit.
All values are presented as n (%) of patients unless otherwise speciﬁed.
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advantages of lower cost, once-daily administration, and feasibility
in outpatient parenteral antibiotic therapy. In the present study,
the choice of ertapenem (rather than imipenem or meropenem)
was reasonable for less severely-ill patients who were at risk of
ESBL-EC bacteremia and unlikely to have a co-infection due to P.
aeruginosa or A. baumannii.
The present study has several limitations. First, it was a non-
concurrent prospective study with the data collected retrospec-
tively at a single teaching hospital. The importance of predictors
(including ertapenem therapy) on survival might be under-
estimated because of the limited sample size in the context that
we excluded non-blood ESBL-producing isolates that might
represent colonization instead of true infection. Second, the
propensity score analysis could only minimize the inﬂuence of
pertinent confounders but could not solve all the bias related to
the underlying differences in the two study populations. Third,
we considered related and unrelated mortality together. Fourth,
the choice of initial antimicrobial agents was mainly based on
physician judgment. Moreover, prescription of ertapenem
required pre-approval by infectious diseases physicians. Finally,
ESBL typing was not performed for any of our isolates.
In conclusion, ICU stay, rather than initial choice of empirical
antimicrobial therapy, was a major predictor of mortality. Using
carbapenem as deﬁnitive therapy was a protective factor for 30-
day mortality. Ertapenem might be a useful alternative to
imipenem or meropenem for the treatment of bacteremia caused
by ESBL-EC in less severely-ill patients who are unlikely to have
infection due to P. aeruginosa.
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